Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Gel agents leads to lower incidence of adhesions at second‐look laparoscopy compared with no gel agents (or placebo) (high certainty).
Zonisamide probably leads to higher 50% responder rate (whole treatment period; any dose) compared with placebo (moderate certainty).
Zonisamide probably leads to higher withdrawal rates (whole treatment period; any dose) compared with placebo (moderate certainty).
Zonisamide may leads to higher adverse effects: ataxia (whole treatment period; any dose) compared with placebo (low certainty).
Zonisamide probably leads to higher adverse effects: dizziness (whole treatment period; any dose) compared with placebo (moderate certainty).
Zonisamide probably leads to higher adverse effects: fatigue (whole treatment period; any dose) compared with placebo (moderate certainty).
Zonisamide probably leads to higher adverse effects: nausea (whole treatment period; any dose) compared with placebo (moderate certainty).
Zonisamide probably leads to higher adverse effects: somnolence (whole treatment period; any dose) compared with placebo (moderate certainty).
Levetiracetam probably leads to higher 50% or greater reduction in focal seizure frequency (responders)… compared with placebo (moderate certainty).
Levetiracetam showed no clear difference in treatment withdrawal– all doses compared with placebo (high certainty).
Levetiracetam probably leads to higher adverse effects: 5 most common adverse effects (any age) – somnolence compared with placebo (moderate certainty).
Levetiracetam showed no clear difference in adverse effects: 5 most common adverse effects (any age) – headache compared with placebo (low certainty).
Levetiracetam showed no clear difference in adverse effects: 5 most common adverse effects (any age) – dizziness compared with placebo (moderate certainty).
Brexpiprazole leads to higher response to treatment at 8 weeks compared with antidepressive agents (high certainty).
Brexpiprazole leads to higher number of dropouts due to any cause at 8 weeks compared with antidepressive agents (high certainty).
Brexpiprazole leads to higher number of dropouts due to adverse effects at 8 weeks compared with antidepressive agents (high certainty).
Brexpiprazole leads to higher remission rates at 8 weeks compared with antidepressive agents (high certainty).